---
category: news
title: "Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC"
excerpt: "OnKai's AI models redefine the methodologies and economics of clinical trials TEL AVIV, Israel, July 10, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) (\"Galmed\" or the \"Company\"), a"
publishedDateTime: 2023-07-10T12:00:00Z
originalUrl: "https://www.benzinga.com/pressreleases/23/07/n33164058/galmed-to-employ-onkais-disruptive-artificial-intelligence-ai-in-its-planned-phase-2a-clinical-tri"
webUrl: "https://www.benzinga.com/pressreleases/23/07/n33164058/galmed-to-employ-onkais-disruptive-artificial-intelligence-ai-in-its-planned-phase-2a-clinical-tri"
ampWebUrl: "https://www.benzinga.com/amp/content/33164058"
cdnAmpWebUrl: "https://www-benzinga-com.cdn.ampproject.org/c/s/www.benzinga.com/amp/content/33164058"
type: article
quality: 54
heat: 54
published: false

provider:
  name: Benzinga.com
  domain: benzinga.com

topics:
  - AI in Healthcare
  - AI

images:
  - url: "https://www.benzinga.com/next-assets/images/schema-image-default.png"
    width: 1043
    height: 1043
    isCached: true

secured: "yPIqTZEwEYCaqPYiBIE6fjV5yfzQsiHskt9O1C9hJqJkcwXlkrJYYp3TptvMhRkwzWVz70keASVt8g20nNXj3K5vBTe9Wah27qaVU4/iZcVU23CGoZ7d0/x/cb2Nt58MlMPr0D4PtluGxVDQ6yYCvlTqG3lPWX9uumDnU8tosAXKHcyFNGxApAcgPrUoWaWzWqF2CnH946smp355IoXn2baKo2XXLKxq8do4YckRYajPnGPNazggV0Wr0PH5JbjHBA6hbcHR9f7XNeowHrwGUu52Sa4c1pvh0lbjewMxzpvOS51VP3Sc0w0i+qN2wTdF264SQo2ILWL0Zxyalph2C9F3+r5RDJfeRKQN8YDPGsY=;NAyWFEqumVcBzOVDG+lzHw=="
---

